

Article

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study

Gabor Liposits ^{1,2,3,*}, Henrik Rode Eshøj ⁴, Sören Möller ^{2,5}, Stine Brændegaard Winther ^{1,3}, Halla Skuladottir ⁶, Jesper Ryg ^{2,3,7}, Eva Hofslí ^{8,9}, Carl-Henrik Shah ¹⁰, Laurids Østergaard Poulsen ¹¹, Åke Berglund ¹², Camilla Qvortrup ³, Pia Österlund ^{13,14,15}, Bengt Glimelius ¹², Halfdan Sorbye ^{16,17} and Per Pfeiffer ^{1,2,3}

Table S1. Bayesian analysis of EORTC QLQ-C30 domain measurements reporting the (posterior) probability of superiority (respectively, non-inferiority/equivalence/inferiority) of SOx compared to S1.

EORTC QLQ-C30 Domains	Change from Baseline to 9-Week Follow-Up				Change from Baseline to 18-Week Follow-Up			
	Superiority	Non-Inferiority	Equivalence	Inferiority	Superiority	Non-Inferiority	Equivalence	Inferiority
	Posterior Probability							
Global QoL	58.60%	99.95%	41.35%	0.05%	4.55%	83.06%	78.51%	16.94%
Physical functioning	49.01%	99.96%	50.95%	0.04%	54.81%	99.90%	45.09%	0.10%
Social functioning	20.84%	97.15%	76.31%	2.85%	24.84%	94.48%	69.64%	5.52%
Role functioning	16.48%	99.43%	82.95%	0.57%	18.99%	98.48%	79.49%	1.52%
Fatigue	0.28%	63.61%	63.33%	36.39%	0.37%	46.41%	46.04%	53.59%
Nausea and vomiting	1.90%	99.83%	97.93%	0.17%	0.07%	88.31%	88.24%	11.69%
Diarrhea	15.68%	89.18%	73.5%	10.82%	12.23%	76.38%	64.15%	23.62%
Pain	0.07%	95.4%	95.33%	4.6%	0.01%	76.12%	76.11%	23.88%
Dyspnea	68.64%	100%	31.36%	0.00%	39.38%	99.72%	60.34%	0.28%




Figure S1. Posterior distribution of difference in global QoL at 9-week follow-up.